Botox sales boost Allergan's bottom line
This article was originally published in Scrip
Forget what the scholarly economic experts and pundits have said about the world economic recession. While the impact of the financial meltdown could be measured by the number of new wrinkles on the faces of Wall Street, the signs of economic recovery could be gauged by new spending for Botox (onabotulinumtoxinA), with Allergan reporting in its fourth-quarter earnings that sales of the drug jumped 11% from $347.7 million in 2009 to $386.2 million in 2010, with cosmetic uses accounting for about half of those sales.
You may also be interested in...
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.